Hand movement video: more promising than photos as a computer vision concept for remote monitoring of RA disease activity. Of course: validation, training, clinical evaluation all must happen before it is ready for your clinic https://t.co/HyN6ElKF0F #ACR23 ABST1293 @RheumNow https://t.co/DltI9HFiFE

Fatigue 😴 in RA & synovial biology In DAS LDA pts Fatigue asso w/ -female sex -synovial lymphocytic inflammation In DAS moderate DA: -female sex -synovial lining layer -Anxiety Limitations: arthroplasty tissue, small sample size, no Immunohisto @RheumNow #ACR23 ABST1630 https://t.co/4vhzvdPgyd

PRES in SLE A#1478 @RheumNow #ACR23 303 cases of Posterior Reversible Encephalopathy Syndrome in SLE - Mean age 28, 91% F - 42% HTN, HLD 15%, DM 10% - 83% lupus nephritis. 80% dsDNA, 41% Sm, 38% aPL - 78% seizures - 3% mortality - Transient in 45%, persistent in 19%, 8% sequelae

#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed primary endpoint, change in ESSDAI was met in DAZ vs PBO. More COVID in DAZ in Stage 1 but trial was at the start of pandemic. Phase 3 is starting soon @RheumNow https://t.co/hZcpOHumB3

Fisher et al. In high disease activity, fatigue associates anxiety and synovial lining hyperplasia, 1.57[1.01,2.5]; p=0.047) In LDA, fatigue associates chronic lymphocytic synovial inflammation, 1.92[1.09,3.57]; p=0.024) Abstr#1630 #ACR23 @RheumNow https://t.co/Gev6pU3srq https://t.co/Ys8etP36ir

Do we miss RA activity in obese pts? Pre-clinical trial entry MSK USS: similar DAS28 but lower SJC/US scores in obese Is it because, in obese RA patients: we underdetect on exam? we undertreat? higher risk, so lower penetrance of severe dx endotypes? #ACR23 ABST1287 @RheumNow https://t.co/3FFPdBJOpz

Vasculitis in SLE A#1443 @RheumNow #ACR23 804 SLE pts, 74% black, 9.5% h/o vasculitis 45% visceral vasculitis, 43% cutanous, 8% both Pts w vasculitis: younger age of SLE dx- 27 v 31y Risks: other SARD, renal dx, neuro dx, low compl Trend to higher mortality 21 to 14% (no signif)

Multimorbidity in #RA - VARA registry data- looking at 61 different biomarkers and 44 comorbidities Chronic pain in 44% Specific biomarkers seen in different morbidities @rheumnow #ACR23 session#13M148 https://t.co/l6FU1ELKD3

Peyton et al.: 4 multimorbidity patterns in RA -Mental health and subst abuse -Metabolic -CV -Chronic pain All associated with different sets of biomarkers. Some are very specific of one profile while others are widespread across profiles. @RheumNow #ACR23 ABST1631 https://t.co/VqCrLI3oyy

Ultrasound (and specifically intima-media thickness) might not just be for diagnosis in GCA - it might be a GCA disease activity measure for monitoring: - improves over time - increases with flares Valentin Schaefer #ACR23 ABST1649 @RheumNow https://t.co/QWdIVGrHbn

Ross et al. Ultrasound assessed Optic nerve sheath measurement in GCA. Previously shown increased in GCA. Here decreases with treatment shown in 9 patients Abstr#1650 #ACR23 @RheumNow https://t.co/fcrS4tT6U0 https://t.co/ylnPKzdUe0

In PS-matched study, no significant difference in respiratory hospitalisation or death between RA-ILD patients on non-TNFi/JAKi vs. TNFi. This finding does not support systematic avoidance of TNFi in RA-ILD, England B Abst#1582 #ACR23 #ACRBest @RheumNow https://t.co/1zVjMWNZZS https://t.co/d8TRIvGaIe

Fate of ANA+/UCTD A#1449 #ACR23 @RheumNow 207 asymptomatic ANA+ or UCTD followed - <10% progress to SARD, 90% did not Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1) Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations

Abst#1583 SMART study: Split dose qwk MTX (10 mg QAM, 15 mg QPM) may have better efficacy compared to 25 mg single dose qwk MTX. RCT 253 RA patients: split dose had better DAS score, less likely to add other DMARDS, but slight⬆️in LFTs. #Plenary #ACR23 @rheumnow #ACRbest